SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 23, 2008. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific transaction notification and does not contain general financial performance data.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary share ADRs for Dr. R G Greig on April 18, 2008, at a price of $43.32 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 18, 2008 (Notification date: April 23, 2008).
- Individual Involved: Dr. R G Greig.
- Transaction Type: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.
- Price per ADR: $43.32.
- Regulatory Basis: Disclosure and Transparency Rule 3.1.4R(1)(a).